Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators

Molecular Therapy Oncolytics

Volumn 4, Issue , 2017, Pages 18-30

  Dyer, Arthur ^a   Di, Ying ^a   Calderon, Hugo ^b   Illingworth, Sam ^b   Kueberuwa, Gray ^a   Tedcastle, Alison ^a   Jakeman, Phil ^a   Chia, Suet Lin ^a   Brown, Alice ^b   Silva, Michael A ^c   Barlow, David ^a   Beadle, John ^b   Hermiston, Terry ^d   Ferguson, David J P ^a   Champion, Brian ^b   Fisher, Kerry D ^a   Seymour, Leonard W ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b PSIOXUS THERAPEUTICS LTD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d BAYER CORPORATION   (United States)

Author keywords

adenovirus; apoptosis; cell death; membrane permeabilization; oncolytic virus; oncosis

Indexed keywords

ADENOSINE TRIPHOSPHATE; B7 ANTIGEN; CALCIUM; CALRETICULIN; CASPASE 3; CASPASE 7; CASPASE 8; CD69 ANTIGEN; CD86 ANTIGEN; CISPLATIN; ENADENOTUCIREV; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LONTUCIREV; ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS 11P; ONCOLYTIC ADENOVIRUS 3; ONCOLYTIC ADENOVIRUS 5; PROTEIN P53; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

A-549 CELL LINE; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL DEATH; CELL STRUCTURE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DRUG POTENCY; ENZYME ACTIVATION; HUMAN; HUMAN ADENOVIRUS B; HUMAN CELL; HUMAN TISSUE; IMMUNOSTIMULATION; IN VITRO STUDY; INFLAMMATION; MCF-7 CELL LINE; MEDIATOR RELEASE; MEMBRANE DAMAGE; MIXED LYMPHOCYTE REACTION; NECROPTOSIS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; UPREGULATION; VIRUS CONCENTRATION;

EID: 85020493071     PISSN: None     EISSN: 23727705     Source Type: Journal    
DOI: 10.1016/j.omto.2016.11.003     Document Type: Article

References (39)

1. 1 Russell, S.J., Peng, K.W., Bell, J.C., Oncolytic virotherapy. Nat. Biotechnol. 30 (2012), 658–670.
2. 2 Seymour, L.W., Fisher, K.D., Oncolytic viruses: finally delivering. Br. J. Cancer 114 (2016), 357–361.
3. 3 Heo, J., Reid, T., Ruo, L., Breitbach, C.J., Rose, S., Bloomston, M., Cho, M., Lim, H.Y., Chung, H.C., Kim, C.W., et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19 (2013), 329–336.
4. 4 Andtbacka, R.H., Kaufman, H.L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K.A., Spitler, L.E., Puzanov, I., Agarwala, S.S., et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33 (2015), 2780–2788.
5. 5 Kuhn, I., Harden, P., Bauzon, M., Chartier, C., Nye, J., Thorne, S., Reid, T., Ni, S., Lieber, A., Fisher, K., et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One, 3, 2008, e2409.
6. 6 Wang, H., Li, Z.Y., Liu, Y., Persson, J., Beyer, I., Möller, T., Koyuncu, D., Drescher, M.R., Strauss, R., Zhang, X.B., et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat. Med. 17 (2011), 96–104.
7. 7 O'Shea, C.C., Choi, S., McCormick, F., Stokoe, D., Adenovirus overrides cellular checkpoints for protein translation. Cell Cycle 4 (2005), 883–888.
8. 8 Scrace, S., O'Neill, E., Hammond, E.M., Pires, I.M., Use of the xCELLigence system for real-time analysis of changes in cellular motility and adhesion in physiological conditions. Methods Mol. Biol. 1046 (2013), 295–306.
9. 9 Weerasinghe, P., Hallock, S., Tang, S.C., Liepins, A., Role of Bcl-2 family proteins and caspase-3 in sanguinarine-induced bimodal cell death. Cell Biol. Toxicol. 17 (2001), 371–381.
10. 10 Weerasinghe, P., Buja, L.M., Oncosis: an important non-apoptotic mode of cell death. Exp. Mol. Pathol. 93 (2012), 302–308.
11. 11 Hallock, S., Tang, S.C., Buja, L.M., Trump, B.F., Liepins, A., Weerasinghe, P., Aurintricarboxylic acid inhibits protein synthesis independent, sanguinarine-induced apoptosis and oncosis. Toxicol. Pathol. 35 (2007), 300–309.
12. 12 Querido, E., Blanchette, P., Yan, Q., Kamura, T., Morrison, M., Boivin, D., Kaelin, W.G., Conaway, R.C., Conaway, J.W., Branton, P.E., Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev. 15 (2001), 3104–3117.
13. 13 Forrester, N.A., Sedgwick, G.G., Thomas, A., Blackford, A.N., Speiseder, T., Dobner, T., Byrd, P.J., Stewart, G.S., Turnell, A.S., Grand, R.J., Serotype-specific inactivation of the cellular DNA damage response during adenovirus infection. J. Virol. 85 (2011), 2201–2211.
14. 14 Sohn, D., Graupner, V., Neise, D., Essmann, F., Schulze-Osthoff, K., Jänicke, R.U., Pifithrin-alpha protects against DNA damage-induced apoptosis downstream of mitochondria independent of p53. Cell Death Differ. 16 (2009), 869–878.
15. 15 McIlwain, D.R., Berger, T., Mak, T.W., Caspase functions in cell death and disease. Cold Spring Harb. Perspect. Biol., 7, 2015, a026716.
16. 16 Buja, L.M., Myocardial ischemia and reperfusion injury. Cardiovasc. Pathol. 14 (2005), 170–175.
17. 17 Trump, B.F., Berezesky, I.K., Chang, S.H., Phelps, P.C., The pathways of cell death: oncosis, apoptosis, and necrosis. Toxicol. Pathol. 25 (1997), 82–88.
18. 18 Kong, K., Kumar, M., Taruishi, M., Javier, R.T., The human adenovirus E4-ORF1 protein subverts discs large 1 to mediate membrane recruitment and dysregulation of phosphatidylinositol 3-kinase. PLoS Pathog., 10, 2014, e1004102.
19. 19 Lieberthal, W., Menza, S.A., Levine, J.S., Graded ATP depletion can cause necrosis or apoptosis of cultured mouse proximal tubular cells. Am. J. Physiol. 274 (1998), F315–F327.
20. 20 Scaffidi, P., Misteli, T., Bianchi, M.E., Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418 (2002), 191–195.
21. 21 Basu, S., Binder, R.J., Suto, R., Anderson, K.M., Srivastava, P.K., Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int. Immunol. 12 (2000), 1539–1546.
22. 22 Brusa, D., Migliore, E., Garetto, S., Simone, M., Matera, L., Immunogenicity of 56 degrees C and UVC-treated prostate cancer is associated with release of HSP70 and HMGB1 from necrotic cells. Prostate 69 (2009), 1343–1352.
23. 23 O'Brien, V., Viruses and apoptosis. J. Gen. Virol. 79 (1998), 1833–1845.
24. 24 Voll, R.E., Herrmann, M., Roth, E.A., Stach, C., Kalden, J.R., Girkontaite, I., Immunosuppressive effects of apoptotic cells. Nature 390 (1997), 350–351.
25. 25 Vaux, D.L., Toward an understanding of the molecular mechanisms of physiological cell death. Proc. Natl. Acad. Sci. USA 90 (1993), 786–789.
26. 26 Jiang, H., White, E.J., Ríos-Vicil, C.I., Xu, J., Gomez-Manzano, C., Fueyo, J., Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity. J. Virol. 85 (2011), 4720–4729.
27. 27 Yun, C.O., Kim, E., Koo, T., Kim, H., Lee, Y.S., Kim, J.H., ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis. Cancer Gene Ther. 12 (2005), 61–71.
28. 28 Abou El Hassan, M.A., van der Meulen-Muileman, I., Abbas, S., Kruyt, F.A., Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. J. Virol. 78 (2004), 12243–12251.
29. 29 Glockzin, G., Mantwill, K., Jurchott, K., Bernshausen, A., Ladhoff, A., Royer, H.D., Gansbacher, B., Holm, P.S., Characterization of the recombinant adenovirus vector AdYB-1: implications for oncolytic vector development. J. Virol. 80 (2006), 3904–3911.
30. 30 Baird, S.K., Aerts, J.L., Eddaoudi, A., Lockley, M., Lemoine, N.R., McNeish, I.A., Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. Oncogene 27 (2008), 3081–3090.
31. 31 Majno, G., Joris, I., Apoptosis, oncosis, and necrosis. An overview of cell death. Am. J. Pathol. 146 (1995), 3–15.
32. 2+ in cell injury, necrosis and apoptosis. Curr. Opin. Cell Biol. 4 (1992), 227–232.
33. 33 Hu, X., Xuan, Y., Bypassing cancer drug resistance by activating multiple death pathways—a proposal from the study of circumventing cancer drug resistance by induction of necroptosis. Cancer Lett. 259 (2008), 127–137.
34. 34 Iyer, S.S., Pulskens, W.P., Sadler, J.J., Butter, L.M., Teske, G.J., Ulland, T.K., Eisenbarth, S.C., Florquin, S., Flavell, R.A., Leemans, J.C., Sutterwala, F.S., Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc. Natl. Acad. Sci. USA 106 (2009), 20388–20393.
35. 35 Thorsteinsson, L., O'Dowd, G.M., Harrington, P.M., Johnson, P.M., The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues. APMIS 106 (1998), 869–878.
36. 36 Brennan, D., Mahoney, M.G., Increased expression of Dsg2 in malignant skin carcinomas: a tissue-microarray based study. Cell Adhes. Migr. 3 (2009), 148–154.
37. 37 Holterman, L., Vogels, R., van der Vlugt, R., Sieuwerts, M., Grimbergen, J., Kaspers, J., Geelen, E., van der Helm, E., Lemckert, A., Gillissen, G., et al. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J. Virol. 78 (2004), 13207–13215.
38. 38 Di, Y., Seymour, L., Fisher, K., Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood. Gene Ther. 21 (2014), 440–443.
39. 39 Sivendran, S., Pan, M., Kaufman, H.L., Saenger, Y., Herpes simplex virus oncolytic vaccine therapy in melanoma. Expert Opin. Biol. Ther. 10 (2010), 1145–1153.